Connect with us

Company News

J&J kicks off study of single-shot COVID-19 vaccine

Johnson & Johnson on Wednesday began a 60,000-person trial of an experimental single-shot COVID-19 vaccine that, if proven effective, could simplify distribution of millions of doses compared with leading rivals requiring two doses.

The J&J vaccine also does not need to be stored at extremely cold temperatures, Dr. Barouch noted, another advantage over some rival vaccine candidates.

The company expects results of the Phase III trial by year end or early next year, and plans to manufacture as many as 1 billion doses in 2021, and more after that. – The Hindu

Copyright © 2024 Medical Buyer

error: Content is protected !!